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Abstract
Background More information is needed about possible
associations between the newer anti-epileptic drugs
(AEDs) in the first trimester of pregnancy and specific
congenital anomalies of the fetus.
Objectives We performed a literature review to find sig-
nals for potential associations between newer AEDs
(lamotrigine, topiramate, levetiracetam, gabapentin,
oxcarbazepine, eslicarbazepine, felbamate, lacosamide,
pregabalin, retigabine, rufinamide, stiripentol, tiagabine,
vigabatrin, and zonisamide) and specific congenital
anomalies.
Methods We searched PubMed and EMBASE to find
observational studies with pregnancies exposed to newer
AEDs and detailed information on congenital anomalies.
The congenital anomalies in the studies were classified
according to the congenital anomaly subgroups of Euro-
pean Surveillance of Congenital Anomalies (EUROCAT).
We compared the prevalence of specific congenital
anomalies in fetuses exposed to individual AEDs in the
combined studies with that of the general population in a
reference database. A significantly higher prevalence based
on three or more fetuses with anomalies was considered a
signal.
Results Topiramate showed a higher rate of congenital
anomalies than the other newer AEDs. Four signals were
found. The signals for associations between topiramate and
cleft lip with/without cleft palate and hypospadias were
considered strong. Associations between lamotrigine and
anencephaly and transposition of great vessels were found
within one study and were not supported by other studies.
No signals were found for the other newer AEDs, or the
information was too limited to provide such a signal.
Conclusion In terms of associations between monotherapy
with a newer AED in the first trimester of pregnancy and a
specific congenital anomaly, the signals for topiramate and
cleft lip with/without cleft palate and hypospadias should
be investigated further.
Key Points
Information was found on specific congenital
anomalies in fetuses exposed to lamotrigine,
topiramate, levetiracetam, gabapentin, and
oxcarbazepine monotherapy in the first trimester.
The possible association between cleft lip and
hypospadias and the use of topiramate in pregnancy
should be investigated further.
1 Introduction
Users of anti-epileptic drugs (AEDs) regularly include
women of childbearing age. During pregnancy, the treat-
ment of epilepsy often needs to be continued, and—if
possible—a pregnant woman with epilepsy should be free
of seizures, because a seizure could harm both mother and
fetus [1]. On the other hand, harm to the fetus from the use
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of medication in pregnancy should also be minimized. A
balance must be found between benefits and risks for
mother and child through agreement between the pregnant
woman and the physician [2, 3]. Objective scientific
information on the risks of AEDs to the fetus is essential
for these discussions and decisions.
AEDs are classified in two groups: older AEDs and
newer AEDs, the latter being introduced during the last
two decades. Since the late 1990s, the use of newer
AEDs has increased, especially for indications other than
epilepsy such as neuropathic pain, mood disorders,
migraine, and depression [4–6]. Lamotrigine, topiramate,
gabapentin, and pregabalin are the most commonly used
newer AEDs [4]. Women in particular seem to use more
newer AEDs than do men, probably in an effort to avoid
the use of valproate during childbearing years [7, 8].
About 0.5 % of pregnant women in Europe use AEDs,
most often carbamazepine, valproic acid, or lamotrigine;
the most frequently used AEDs differ between countries
[9].
More information is needed on the risk of congenital
anomalies in exposed pregnancies for the newer AEDs.
These newer AEDs might have an increased risk for
specific congenital malformations. We performed an
extensive literature search to find signals of higher risks of
specific congenital anomalies in relation to the use of
newer AEDs in pregnancy.
2 Methods
2.1 Search Strategy
The newer AEDs included in this review were lamotrigine,
topiramate, levetiracetam, gabapentin, oxcarbazepine,
eslicarbazepine, felbamate, lacosamide, pregabalin, reti-
gabine, rufinamide, stiripentol, tiagabine, vigabatrin, and
zonisamide.
We searched PubMed for original articles using the
following search strategy:
1. congenital abnormalities [medical subject heading;
MeSH] OR pregnancy complications/drug therapy OR
pregnancy complications/drug effects OR pregnancy
outcome [MeSH]
AND
2. (felbamate OR gabapentin OR lacosamide OR lamot-
rigine OR levetiracetam OR pregabalin OR topiramate
OR vigabatrin OR eslicarbazepine OR oxcarbazepine
OR rufinamide OR stiripentol OR zonisamide OR
tiagabine OR retigabine OR pheneturide) NOT (mod-
els, animal [MeSH] OR animal experimentation
[MeSH]).
We searched EMBASE for all newer AEDs separately
using the following search strategy:
‘lamotrigine (or other drug) AND congenital malfor-
mation AND pregnancy NOT review’.
The search was conducted on 12 November 2014.
2.2 Selection
The articles were selected using the following inclusion
criteria:
– original randomized controlled trials or observational
studies.
– exposure to a newer AED as monotherapy in the first
trimester (B12 weeks of gestation).
– information on congenital anomalies.
– the most recent update of studies based on the same
long-term databases or pregnancy registries.
– enrolment of the pregnant women before the outcome
of the pregnancy was known in the cohort and
observational studies.
The articles from PubMed were selected based on the
title and abstract. They were classified into two groups
(studies including one AED and studies including more
than one AED) and were read carefully, including the
appendices. The articles were selected based on the
inclusion criteria and categorised per AED; thus, the arti-
cles with more than one AED were categorised more than
once. Additional articles found in EMBASE or the refer-
ences that met the inclusion criteria were added (Fig. 1).
2.3 Data Extraction
We reclassified the selected studies into five types based on
the study design, which could differ from the design indi-
cated by the authors:
1a. prospective cohort studies (with reference group).
1b. retrospective cohort studies (with reference group).
2a. prospective exposed groups (without reference group).
2b. retrospective exposed groups (without reference group).
3. case–control studies.
We analysed studies that included stillbirths, fetal
deaths, and pregnancy terminations (‘all births’) and
studies describing only live births both separately and in
combination.
2.4 Data Analysis
Two authors (JJ and EG) reclassified all specific congenital
anomalies into the congenital anomaly subgroups of the
European Surveillance of Congenital Anomalies (EURO-
CAT) [10]. Only major anomalies were included in the
132 J. de Jong et al.
Fig. 1 Selection process for articles included in the review
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analysis. When no information was provided on specific
congenital anomalies, we followed the definition of major
congenital anomalies in the article.
We calculated the overall major anomaly rate for every
AED, for which cohort studies or studies with exposed
groups (1a, 1b, 2a, and 2b) were selected, using the
number of fetuses as the denominator. If the analysis in
an article was based on pregnancies, and the exact num-
ber of fetuses was unknown, we used the number of
pregnancies, assuming that multiple pregnancies are rare
and that this difference would not greatly influence the
results.
We calculated the prevalence of any specific congenital
anomaly subgroup from studies with sufficiently detailed
information.
The prevalence of specific anomalies was compared
with the prevalence of the anomaly subgroup in the
EUROCAT AED database, which covers 10,061,059 births
from 21 regions in Europe (1995–2011) and has been
described previously [11, 12]. We excluded registrations
from this database with maternal AED exposure, maternal
epilepsy, or chromosomal anomalies. A significantly higher
prevalence of a specific congenital anomaly, based on three
or more fetuses with anomalies among fetuses exposed to
newer AEDs compared with the prevalence in the reference
database, was considered a signal. This procedure is based
on the method used by Jentink et al. [12] (see the Elec-
tronic Supplementary Material [ESM], Sect. 2), who sear-
ched for signals for investigation in a case–control study
and noted that it is preferable to detect only the strongest
signals. If one or two fetuses with a specific congenital
anomaly are found within all the literature searched, it
could be that coincidence may have played a major role.
We decided to draw the limit at three or more fetuses with
a specific anomaly. The case-control studies found were
not included in the analysis but were summarized
separately.
2.5 Statistical Analysis
We calculated the anomaly rate and confidence interval
using the method described by Newcombe [13]: the Wilson
‘score’ method. To compare the prevalence of specific
congenital anomalies in the fetuses exposed to newer
AEDs with those in the reference database, we used
Pearson’s Chi-squared test and Yates’ continuity correc-
tion. We used Microsoft Office Excel (Microsoft Corp.,
Redmond, WA, USA) and R version 3.1.0 (Free Software,
Free Software Foundation, Boston, MA, USA) software for
the data analysis. A p value\0.05 was considered statis-
tically significant.
3 Results
3.1 General Results
We selected 341 articles from PubMed. In addition, six
articles from EMBASE and references were added (Fig. 1;
grey background). The 30 selected studies were catego-
rized per AED and study design, as shown in Table 1. We
found no randomized controlled trials.
Table 2 shows an overview of the cohort- and exposed
group studies found, with the numbers of fetuses or preg-
nancies exposed to lamotrigine, topiramate, levetiracetam,
gabapentin, or oxcarbazepine and the percentage of major
congenital anomalies. Vajda et al. [14] provided no infor-
mation on whether the congenital anomalies were major or
minor, so we counted the total number of congenital
anomalies. One study [15] included only live births.
Two studies were based on international pregnancy
registries and were analysed separately: Cunnington et al.
[16] used the International Lamotrigine Pregnancy Reg-
istry, with information on specific congenital anomalies of
fetuses exposed to lamotrigine; Tomson et al. [17] based
their study on the European Registry of Antiepileptic
Drugs and Pregnancy (EURAP), a registry of pregnancies
exposed to all types of AEDs in 42 countries. The latter
provided only information about some congenital anomaly
subgroups from pregnancies exposed to newer AEDs.
Whether the congenital anomalies were major or minor
was not defined, so we used the total number of congenital
anomalies to calculate the anomaly rate.
No congenital anomaly was found in fetuses exposed to
felbamate, lacosamide, pregabalin, tiagabine, vigabatrin, or
zonisamide, but the number of exposed fetuses was very
low (1 to 10), except for zonisamide (n = 97). No studies
describing exposed pregnancies were found for eslicar-
bazepine, retigabine, rufinamide, or stiripentol.
The studies based on the International Lamotrigine
Pregnancy Registry [16] and EURAP registry [17], both
international pregnancy registries, were analysed sepa-
rately because they involve data from, respectively, 43 and
42 countries and might overlap with the other studies.
Table 3 shows the prevalence of specific congenital
anomaly subgroups according to the EUROCAT classifi-
cations based on the studies with information on specific
congenital anomalies compared with that in the reference
(EUROCAT AED) database. Two studies [18, 19] with
information on congenital anomaly subgroups on a higher
level (e.g., ‘nervous system’ or ‘cardiovascular heart
defects’) among lamotrigine-exposed pregnancies were
included in the calculation of the prevalence of these
higher-level subgroups, using another denominator.
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Table 4 is a summary of the odds ratios (ORs) found in
the three selected case–control studies. These case–control
studies used databases of pregnancies with congenital
anomalies and the (adjusted) ORs of specific congenital
anomalies was determined comparing use and no use of
specific AEDs.
3.2 Lamotrigine
A total of 5197 fetuses exposed to lamotrigine monother-
apy in the first trimester were described, 123 of which had
major congenital anomalies. The anomaly rate was 2.3 %
in the studies with all births; inclusion of the study with
only live births [15] changed the rate to 2.4 % (Table 2). In
the International Lamotrigine Pregnancy Registry [16], the
anomaly rate was 1.7 %. The study based on the EURAP
registry [17] reported an anomaly rate of 2.9 %.
The analysis of specific congenital anomalies is based
on seven studies [18–24]. The data from the International
Lamotrigine Pregnancy Registry [16] were also compared
with the reference database (Table 3). For most specific
congenital anomalies, the prevalence among fetuses
exposed to lamotrigine monotherapy in the first trimester is
comparable with the prevalence of the reference database.
In the analysis based on the International Lamotrigine
Pregnancy Registry [16], the specific congenital anomalies
anencephaly and transposition of great vessels were sig-
nificantly more prevalent than in the reference database,
based on three or more fetuses with anomalies (1.77 vs.
0.20/1000, p\ 0.001; 1.77 vs. 0.30/1000, p = 0.005,
respectively).
In two case–control studies by Dolk et al. [25] (case-
malformed–control study) and Werler et al. [26], no
association between the use of lamotrigine in pregnancy
and congenital anomalies was found (Table 4).
3.3 Topiramate
In seven studies, 553 fetuses were exposed to topiramate,
20 of whom had congenital anomalies (Table 2). The
anomaly rate was 3.6 % without and with the study
including only live births [15], which was higher than for
the other newer AEDs. The study based on the EURAP
registry [17] reported an anomaly rate of 6.8 %. The
prevalence of specific congenital anomalies was calculated
from six studies [14, 15, 20, 21, 27, 28]. Two specific
congenital anomalies were significantly more prevalent,
based on three or more fetuses with anomalies, in the
fetuses exposed to topiramate than in the reference data-
base: cleft lip with or without cleft palate (13.86 vs. 0.84/
1000, p\ 0.001) and hypospadias (7.92 vs. 1.53/1000,
p = 0.002) (Table 3).
The case–control study by Margulis et al. [29] found an
OR[1 for cleft lip with/without palate for pregnancies
exposed to topiramate.
3.4 Levetiracetam
The major congenital anomaly rate of fetuses exposed to
levetiracetam monotherapy in the first trimester was 1.1 %
(11 of 957) and 1.6 % in the EURAP study [17]. Three
studies provided specific information on congenital
anomalies [20, 30, 31]. Based on three or more cases
among fetuses exposed to levetiracetam, no congenital
anomaly was more prevalent than in the reference database
(Table 3).
Table 1 Number of included studies, stratified by anti-epileptic drug and study design
Study design LTG TPM LEV GBP OXC FBM LCS TGB VGB ZNS PGB Total
1a: prospective
cohort study
3 [14, 20,
24]
4 [14,
20, 27,
28]
2 [14,
20]
4 [14, 20,
32, 35]
4 [14, 20,
38, 40]
0 0 1
[14]
1
[14]
1
[20]
0 20
1b: retrospective
cohort study
2 [19, 21] 2 [19,
21]
1 [19] 1 [21] 3 [19, 21,
39]
0 0 0 0 0 0 9
2a: prospective
exposed group
5 [16–18,
22, 23]
1 [17] 2 [17,
30]
2 [17, 33] 3 [17, 36,
37]
1
[17]
1
[17]
0 1
[17]
1
[17]
1
[17]
18
2b: retrospective
exposed group
1 [15] 1 [15] 1 [31] 2 [15, 34] 1 [15] 0 0 0 1
[15]
1 0 8
3: case–control study 2 [25, 26] 1 [29] 0 0 0 0 0 0 0 0 0 3
Total 13 9 6 9 11 1 1 1 3 3 1 58a
FBM felbamate, GBP gabapentin, LCS lacosamide, LEV levetiracetam, LTG lamotrigine, OXC oxcarbazepine, PGB pregabalin, TGB tiagabine,
TPM topiramate, VGB vigabatrin, ZNS zonisamide
a 30 studies, of which six are counted several times into different drug groups: two prospective cohort studies: one including six individual
antiepileptics and one including seven individual antiepileptics; two retrospective cohort studies: one including four and one including three
individual antiepileptics; one prospective exposed group including nine individual antiepileptics; one retrospective exposed group including five
individual antiepileptics
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Table 2 Overview of the studies including fetuses/pregnancies exposed to monotherapy with antiepileptic drugs in the first trimester
Study Country Birth years Fetuses/
pregnancies
No. exposed No. of congenital
anomaliesa
Drug
Mawer et al. [21]b UK 2000–2006 F 37 2 Lamotrigine
3 0 Topiramate
2 0 Gabapentin
Herna´ndez-Dı´az et al. [20] USA 1997–2011 F 1562 24c Lamotrigine
359 13c Topiramate
450 6c Levetiracetam
145 1 Gabapentin
182 4 Oxcarbazepine
Vajda et al. [14]d Australia 1998–2013 F 310 15 Lamotrigine
43 1 Topiramate
83 2 Levetiracetam
10 0 Gabapentin
17 1 Oxcarbazepine
Veiby et al. [19] Norway 1999–2011 F 833 28 Lamotrigine
48 2 Topiramate
118 2 Levetiracetam
57 1 Oxcarbazepine
Meador [22] USA/UK 1999–2004 F 98 1 Lamotrigine
Miskov et al. [23] Croatia 2003–2008 P 23 0 Lamotrigine
Cassina et al. [24] Italy 2000–2008 P 46 0 Lamotrigine
Campbell et al. [18] UK/Ireland 1996–2012 F 2198 49 Lamotrigine
Hunt et al. [27] UK 1996–2007 F 70 3 Topiramate
Ornoy et al. [28] Israel 1996–2006 F 29 1 Topiramate
Ten Berg et al. [31] The Netherlands – F 2 0 Levetiracetam
Mawhinney et al. [30] UK/Ireland 2000–2011 P 304 1c Levetiracetam
Montouris [34] USA – P 17 0c Gabapentin
Morrow et al. [35] UK 1996–2005 P 31 1 Gabapentin
Guttusso et al. [33] USA 2008–2009 F 7 2 Gabapentin
Fujii et al. [32] Diversee – P 36 0 Gabapentin
Samren et al. [41] The Netherlands 1972–1994 F 2 0 Oxcarbazepine
Hvas et al. [40] Denmark 1989–1997 F 7 0 Oxcarbazepine
Kaaja et al. [37]f Finland 1990–1998 F 9 1 Oxcarbazepine
Meischenguiser et al. [36] Argentina 1995–2002 F 35 0 Oxcarbazepine
Artama et al. [39] Finland 1991–2000 F 99 1 Oxcarbazepine
Viinikainen et al. [38]f Finland 1989–2000 F 2 0 Oxcarbazepine
Totalg 5107
[2.3 (2.0–2.8)]
119 Lamotrigine
552
[3.6 (2.3–5.5)]
20 Topiramate
957
[1.1 (0.6–2.0)]
11 Levetiracetam
248
[1.6 (0.6–4.0)]
4 Gabapentin
410
[2.0 (0.9–3.8)]
8 Oxcarbazepine
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3.5 Gabapentin
Four of 266 fetuses exposed to gabapentin in the first tri-
mester had major congenital anomalies (Table 2). Con-
genital anomalies were not found in the study that included
only live births [15] or in the EURAP study [17]. The
overall anomaly rate was 1.5 %. We used seven studies
with detailed information [15, 21, 28, 32–35] for the
analysis of specific major congenital anomalies. No sig-
nificant differences were found between the prevalence of
the specific congenital anomalies and the prevalence in the
reference database (Table 3).
3.6 Oxcarbazepine
Eight of 414 fetuses exposed to oxcarbazepine in the first
trimester of pregnancy had major congenital anomalies. The
anomaly rate was 2.0 % of the studies with all births and
1.9 % including the study with live births [15]. The EURAP
study [17] had an anomaly rate of 3.3 %. The prevalence of
Table 2 continued
Study Country Birth years Fetuses/
pregnancies
No. exposed No. of congenital
anomaliesa
Drug
Studies including only live births
Wide [15] Sweden 1995–2001 F 90 4 Lamotrigine
1 0 Topiramate
18 0 Gabapentin
4 0 Oxcarbazepine
Total (studies including
only live births)g
5197
[2.4 (2.0–2.8)]
123 Lamotrigine
553
[3.6 (2.4–5.5)]
20 Topiramate
957
[1.1 (0.6–2.0)]
11 Levetiracetam
266
[1.5 (0.6–2.0)]
4 Gabapentin
414
[1.9 (1.0–3.8)]
8 Oxcarbazepine
International Pregnancy Registry Studies
Cunnington et al. [16]g International Lamotrigine
Pregnancy Registryc
1992–2010 F 1699
[1.7 (1.2–2.4)]
29 Lamotrigine
Tomson et al. [17]g EURAP Registryh 1999–2010 F 1280
[2.9 (2.1–4.0)]
37 Lamotrigine
73
[6.8 (3.0–15.0)]
5 Topiramate
126
[1.6 (0.4–5.6)]
2 Levetiracetam
23
[NA]
0 Gabapentin
184
[3.3 (1.5–6.9)]
6 Oxcarbazepine
EURAP European Registry of Antiepileptic Drugs and Pregnancy, F fetus, NA not applicable, P pregnancy
a Number of fetuses with one or more major congenital anomalies
b Possible overlap with Herna´ndez-Dı´az et al
c Excludes fetuses with minor anomalies
d Major and minor anomalies not separated
e Canada, France, England, Italy, Korea
f Possible overlap with Artama et al
g Data are presented as [major congenital anomaly rate % (95 % confidence interval)]
h Includes major and minor congenital malformation
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Table 3 Prevalence of specific anomaly subgroups of fetuses/pregnancies exposed to lamotrigine, topiramate, levetiracetam, gabapentin, or
oxcarbazepine compared with the reference database
Congenital anomaly Prevalence (no. cases, no. studies) Prevalence (no.
cases)
Lamotrigine Lamotrigine
International
Pregnancy
Registry [16]
Topiramate Levetiracetam Gabapentin Oxcarbazepine EUROCAT AED
database
(reference)
(N = 10,061,059)
Nervous system 2.08 (10, 4) 2.35 (4, 1) 1.32 (1, 1) 8.26 (1, 1) 1.67 (16,752)
Unspecified [16, 20, 21,
33]
NA (2, 2) NA (1, 1) NA (1, 1)
Anencephalus and
similar [16, 20]
0.57 (1, 1) 1.77a (3, 1) 1.32 (1, 1) 0.2 (1977)
Spina bifida [20] 0.57 (1, 1) 0.4 (4005)
Hydrocephalus [20] 0.57 (1, 1) 0.39 (3946)
Arhinencephaly/
holoprosencephaly [20]
1.13 (2, 1) 0.06 (565)
Eye 1.32 (1, 1) 0.38 (3820)
Congenital cataract [20] 1.32 (1, 1) 0.09 (943)
CHDb 7.50 (36, 4) 5.30 (9, 1) 5.94 (3, 2) 1.32 (1, 1) 8.26 (1, 1) 6.71 (67,535)
Unspecified [28] NA(1, 1)
Transposition of great
vessels [16, 20]
0.57 (1, 1) 1.77a (3, 1) 0.30 (2988)
VSD [16, 20, 22, 35] 0.57 (1, 1) 1.77 (3, 1) 1.98 (1, 1) 1.32 (1, 1) 8.26 (1, 1) 3.34 (33,642)
ASD [20] 2.27 (4, 1) 1.98 (1, 1) 1.94 (19,484)
Tetralogy of Fallot [16] 0.59 (1, 1) 0.24 (2416)
Pulmonary valve
stenosis [16, 20]
0.57 (1, 1) 0.59 (1, 1) 0.34 (3450)
Pulmonary valve atresia
[20]
0.57 (1, 1) 0.08 (853)
Hypoplastic left heart
[16]
1.18a (2, 1) 0.19 (1910)
Patent ductus arteriosus
[20]
1.98 (1, 1) 0.33 (3330)
Respiratory 0.63 (3, 2) 1.98 (1, 1) 2.94 (1, 1) 0.44 (4406)
Unspecified [20] NA (1, 1)
Choanal atresia [20] 0.57 (1, 1) 0.06 (569)
Cystic adenomatous
malformation of lung
[20]
2.94a (1, 1) 0.03 (338)
Orofacial clefts 2.08 (10, 3) 1.18 (2, 1) 13.86a (7,
2)
2.94 (1, 1) 1.36 (13,720)
Cleft lip with or without
palate [16, 20, 27]
2.27 (4, 1) 0.59 (1, 1) 13.86a (7,
2)
0.84 (8470)
Cleft palate [16, 20] 1,70 (3, 1) 0.59 (1, 1) 2.94 (1, 1) 0.52 (5247)
Digestive system 2.50 (12, 2) 1.77 (3, 1) 1.98 (1, 1) 3.97 (3, 2) 1.45 (14,604)
Oesophageal atresia
with or without trachea
oesophageal fistula [30]
1.32 (1, 1) 0.21 (2138)
Duodenal atresia or
stenosis [20]
1.98a (1, 1) 0.08 (834)
Atresia or stenosis of
other parts of small
intestine [20]
1.32a (1, 1) 0.06 (593)
Ano-rectal atresia and
stenosis [16, 20]
0.59 (1, 1) 1.32 (1, 1) 0.94 (2668)
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specific congenital anomalies was calculated by including
eight studies [15, 20, 36–41] (Table 3). Based on three or
more cases, no higher prevalence of specific congenital
anomalies than in the reference database was found.
4 Discussion
In this literature review, we found 30 articles that met our
inclusion criteria. The total major anomaly rate of fetuses
exposed to topiramate was slightly higher than of those
exposed to the other newer AEDs. The anomaly rate for the
EURAP study [17] was higher, probably because minor
anomalies were included.
No congenital anomalies were found among pregnancies
exposed to felbamate, lacosamide, pregabalin, tiagabine,
vigabatrin, or zonisamide. Because the number of obser-
vations is very low, no conclusions could be drawn about
the risk of congenital anomalies for pregnancies exposed to
these AEDs. No articles on congenital anomalies were
found in relation to the use of eslicarbazepine, retigabine,
rufinamide, or stiripentol.
Four signals of possible associations of specific con-
genital anomalies and use of newer AED monotherapy in
the first trimester of pregnancy were detected: two related
to lamotrigine (anencephaly and transposition of great
vessels) and two related to topiramate (cleft lip with or
without cleft palate and hypospadias).
Table 3 continued
Congenital anomaly Prevalence (no. cases, no. studies) Prevalence (no.
cases)
Lamotrigine Lamotrigine
International
Pregnancy
Registry [16]
Topiramate Levetiracetam Gabapentin Oxcarbazepine EUROCAT AED
database
(reference)
(N = 10,061,059)
Diaphragmatic hernia
[16]
1.18a (2, 1) 0.20 (1985)
Urinary 0.57 (1, 1) 1.77 (3. 1) 1.98 (1, 1) 1.32 (1, 1) 8.26 (1, 1) 2.94 (1, 1) 2.45 (24,649)
Unspecified [20] NA (1, 1)
Renal dysplasia [20] 1.32 (1, 1) 0.23 (2364)
Congenital
hydronephrosis [16, 33,
37]
1.77 (3, 1) 8.26 (1, 1) 2.94 (1, 1) 0.85 (8519)
PUV and/or prune belly
[20]
0.57 (1, 1) 0.08 (793)
Genital 1.92 (5, 2) 1.92 (5, 2) 7.92a (4, 2) 5.88 (2, 2) 1.80 (18,115)
Unspecified [39] NA (1, 1)
Hypospadias [20, 28]c 0.57 (1, 1) 1.18 (2, 1) 7.92a (4, 2) 2.94 (1, 1) 1.53 (15,395)
Limb 2.27 (4, 2) 3.53 (6, 1) 7.92 (4, 1) 2.94 (1, 1) 3.94 (39,652)
Limb reduction [20] 1.13 (2, 1) 1.98 (1, 1) 0.51 (5162)
Club foot [16, 20, 21] 0.57 (1, 1) 1.77 (3, 1) 1.98 (1, 1) 0.90 (9042)
Hip dislocation and/or
dysplasia [16, 20]
0.59 (1, 1) 2.94 (1, 1) 0.58 (5814)
Polydactyly [16, 20] 0.57 (1, 1) 1.18 (2, 1) 1.98 (1, 1) 0.87 (8789)
Syndactyly [20] 1.98 (1, 1) 0.46 (4660)
Other
Craniosynostosis [20] 0.57 (1, 1) 0.17 (1737)
Congenital skin
disorder [16]
0.59 (1, 1) 0.22 (2232)
AED anti-epileptic drug, ASD atrial septal defect, CHD congenital heart defect, EUROCAT European Surveillance of Congenital Anomalies, NA
not applicable, PUV posterior urethral valve, VSD ventricular septal defect
a Significant difference
b One infant with transposition of great vessels, ASD, and pulmonary valve atresia, one infant with transposition of great vessels and tetralogy of
Fallot, and one infant with VSD and ASD were counted once within the total number of CHD
c The only anomaly of topiramate monotherapy in the study by Vajda et al. [14] was hypospadias according to a previous article [46]
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4.1 Lamotrigine
Two signals were found in the analysis of the study based
on the International Lamotrigine Pregnancy Registry [16].
The first signal was a significantly higher prevalence of
anencephaly (three cases) compared with the reference
database. Anencephaly was also found in the analysis of
the other combined studies but not significantly more fre-
quently than in the reference database. The high prevalence
of anencephaly was mentioned in the discussion of the
study [16], but an association was not concluded because
this finding was not supported by other studies.
The prevalence of transposition of great vessels is higher
in the International Lamotrigine Pregnancy Registry [16]
than in the reference database. In the combined analysis,
transposition of great vessels was found; however, the
prevalence was similar to that in the reference database.
Cunnington et al. [16] stated that several cases of severe
cardiac defects were found but that other studies fail to
support an increased frequency of cardiac heart defects
among fetuses exposed to lamotrigine in utero.
In this review, we did not find an association between
lamotrigine and orofacial clefts, which was one of the
conclusions in a previous review [42]. This conclusion was
based on studies from the North American AED Pregnancy
Registry, which found an increased frequency of isolated
cleft palate in infants exposed to lamotrigine during preg-
nancy compared with the reference population [20, 43].
The case-malformed–control study by Dolk et al. [25] did
not find an association between lamotrigine and orofacial
clefts. A letter responding to the review stated that the
comparison group in the North American AED Pregnancy
Registry had a low prevalence of orofacial clefts compared
with other databases [44]. In the case–control study by
Werler et al. [26] in the USA, based on the National Birth
Defect Prevention Study, no significant association was
found between orofacial clefts and lamotrigine. That we
did not find signals of an association between orofacial
clefts and lamotrigine exposure in pregnancy, combining
all known cohort studies, supports that there is no associ-
ation between lamotrigine and orofacial clefts.
4.2 Topiramate
We found a signal for the congenital anomaly subgroup
cleft lip with or without palate in fetuses exposed to topi-
ramate in the first trimester of pregnancy. The prevalence is
significantly higher than in the reference database and is
based on seven fetuses. Five of these were from the study
by Herna´ndez-Dı´az et al. (North American AED Pregnancy
Registry) [20], and two were from the study by Hunt et al.
(UK Epilepsy and Pregnancy Register) [27]. The conclu-
sion of the study by Herna´ndez-Dı´az et al. [20] mentioned
an association between topiramate monotherapy use in
pregnancy and cleft lip. The conclusion of the study by
Hunt et al. [27] also mentioned an association between
topiramate and orofacial clefts, but their analysis was based
on two fetuses with exposure to topiramate as monotherapy
and two fetuses with topiramate in combination with other
AEDs. The case–control study by Margulis et al. [29],
using two North-American databases, found an association
between topiramate and cleft lip with or without palate.
Mines et al. [45] used four different data sources from the
USA and found a higher prevalence of cleft lip in infants
Table 4 Summary of the selected case–control studies
Study AED Database Congenital anomaly OR (95 % CI) (use/no use)
Dolk et al. [25] Lamotrigine EUROCAT Isolated orofacial clefts 0.80 (0.11–2.85)
Isolated and multiple orofacial clefts 0.67 (0.10–2.85)
Isolated cleft palate 1.01 (0.03–5.57)
Isolated and multiple cleft palate 0.79 (0.03–4.35)
Werler et al. [26] Lamotrigine NBDPS Oral clefts 4.3 (0.71–26.2)
Heart defects 1.7 (0.31–9.3)
Hypospadias 2.7 (0.17–44.0)
Other 1.2 (0.17–8.4)
Margulis et al. [29] Topiramate BDS Any major 1.22 (0.19–13.01)
Cleft lip with/without palate 10.13 (1.09–129.21)
NBDPS Any major 0.92 (0.26–4.06)
Cleft lip with/without palate 3.63 (0.66–20.00)
Pooled Any major 1.01 (0.37–3.22)
Cleft lip with/without palate 5.36 (1.49–20.07)
AED anti-epileptic drug, BDS Slone Epidemiology Center Birth Defects Study, CI confidence interval, EUROCAT European Surveillance of
Congenital Anomalies, NBPDS National Birth Defects Prevention Study, OR odds ratio, pooled indicates that these databases are pooled
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exposed to topiramate monotherapy than in infants of
mothers formerly exposed to topiramate or other AEDs and
mothers with similar medical profiles not exposed to
topiramate. We conclude there is a strong signal indicating
an association between cleft lip and topiramate
monotherapy in the first trimester of pregnancy. This signal
should be investigated further.
The second signal among fetuses exposed to topiramate
monotherapy in the first trimester of pregnancy was a
higher risk of hypospadias. Four fetuses with hypospadias
were found in three different studies: one from the study by
Vajda et al. (Australian Pregnancy Registry) [14], one from
the study by Hunt et al. (UK Epilepsy and Pregnancy
Register) [27], and two from the study by Herna´ndez-Dı´az
et al. (North American AED Pregnancy Registry) [20].
Prevalence was significantly higher than in the reference
database. Neither Herna´ndez-Dı´az et al. [20] nor Hunt et al.
[27] mentioned a possible association between hypospadias
and the use of topiramate monotherapy in their conclu-
sions. Vajda et al. [28] also did not mention this association
in their conclusion. Although they did indicate an associ-
ation in a previous study [46], it was not for monotherapy.
4.3 Strengths and Limitations
A limitation of this review was the small sample size of
fetuses exposed to newer AEDs in the observational studies
included in the analysis of specific congenital anomalies.
The number of exposed fetuses with information for
specific congenital anomalies was 505 for topiramate, 756
for levetiracetam, 125 for gabapentin, and 340 for oxcar-
bazepine. The specific congenital anomaly subgroups with
a prevalence of 0.1–5/1000 are most likely missed in these
small samples. For lamotrigine, the number of pregnancies
with information on specific congenital anomalies was
higher (n = 1766 and 1699 from the International
Lamotrigine Pregnancy Registry [16]), which increased the
chance of finding signals.
We found few or no exposed fetuses for six other newer
AEDs, except for zonisamide (97 exposed fetuses) and no
congenital anomalies. We found no studies on exposure in
pregnancy for five newer AEDs and therefore could draw
no conclusions on possible associations with specific con-
genital anomalies.
Another limitation is that enrolment in most of the
studies was voluntary. Selection bias may be present
because well-educated, motivated, or interested women are
more likely to register. It was unknown for most preg-
nancies whether the women took medication (prescribed or
over the counter) other than the AEDs. This possible co-
medication could also be teratogenic, as could other
exposures such as smoking and alcohol use or other
unknown circumstances affecting the fetus.
Not all the studies excluded chromosomal anomalies. A
few major congenital anomalies from fetuses with chro-
mosomal anomalies may have been included. Because we
reclassified the anomalies according to EUROCAT, we
consider this will not affect the results.
Differences also exist between the cohorts used in the
literature and those in the EUROCAT AED database. The
latter contains data from 1995 to 2011, whereas the liter-
ature includes studies with data from earlier years, starting
from 1972 [41]. Because the data before 1995 are sparse,
we consider this unlikely to have affected the conclusions.
However, the data from the EUROCAT AED database are
mainly from Europe, whereas the literature includes studies
from the USA. In particular, one important study with
considerable data is from the USA [20]. However, we think
the differences between the populations are not large
enough to affect the results.
5 Conclusion
In this literature review, we sourced information on
specific congenital anomalies in fetuses exposed to lam-
otrigine, topiramate, levetiracetam, gabapentin, or oxcar-
bazepine monotherapy in the first trimester. Few or no
exposed pregnancies and no congenital anomalies were
reported for the remaining AEDs. Four signals of possible
associations between the use of newer AEDs and specific
congenital anomalies were detected: lamotrigine and
anencephaly, lamotrigine and transposition of great ves-
sels, topiramate and cleft lip, and topiramate and
hypospadias. Of these, only the signal for the association
between topiramate and cleft lip with or without cleft
palate was considered strong. There might be an associ-
ation between hypospadias and the use of topiramate in
pregnancy, but possibly only for polytherapy. These sig-
nals should be investigated further.
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